Skip to content
Read • Question • ConnectAnthony’s notes & researchReturn with a new question
Anthony’s NotesA personal field guide
From the notebook

Source - Shapiro - 4 Myths About American Healthcare (Claim Audit)

Ben Shapiro / Daily Wire monologue. Filed as an audited source, not as material. The core thesis — that US medical innovation is real, disproportionate, and financed by risk capital that price controls would damage — is the strongest supply-side case available and is worth having. But the empirical support is uneven, and two of the four “myth-busts” are inverted: the evidence he cites cuts against him.

Thesis in one line

American healthcare’s problems are administrative and regulatory, not capitalist; the US supplies the world’s medical innovation because of its uniquely deep risk-capital markets; Medicare for All would kill the mechanism that produces the innovation, and foreign price controls — not corporate greed — are why Americans overpay for drugs.

Claim audit

Holds up

Innovation lead is real, directionally. The US is the disproportionate global source of biopharmaceutical R&D and novel drug origination. Direction is not seriously disputed.
But: the specific figures (35% of global clinical trials, 50%+ of early-phase high-risk trials, 55% of global biopharma R&D, “20 of 27 major innovations”) are given without citation and several are likely dated — China’s share of clinical trials has risen sharply. Do not use these numbers until sourced to a primary document.

Risk capital as the differentiator (25:52 Bezos clip, 7:26–8:52). Genuinely the most interesting argument in the piece: the US difference is not the tax code or the banking system but the willingness to raise $50M of seed capital against a 10% success probability. This is a real structural feature and it does map onto pharma’s failure economics.

Innovation diffuses from luxury to necessity (21:16–22:09). Sound general principle, well illustrated.

Administration and regulatory compliance are a genuine cost problem. True in kind. See below for the magnitude.

Old-age spending concentration (17:15–18:04). The 65+ figures — 17% of population, 37% of spending, ~$22.4k per capita in 2020 — track CMS Age and Gender NHE data. Plausible; verify against source before citing.

Real argument, unsupported mechanism

Foreign free-riding on drug prices (9:07, 26:14–27:38). The free-riding claim is legitimate and has serious backing — the 2018 Council of Economic Advisers report made this case at length. It is a genuine policy debate, not a talking point.

The problem is the proposed mechanism. He claims that forcing Britain to pay US prices would lower US prices — “our price will be lower, their price will be slightly higher.” Nothing in monopoly pricing produces this. A firm with pricing power sets each market at what that market will bear; there is no fixed global revenue target that redistributes downward when one market’s price rises. Raising foreign prices raises firm revenue; it does not mechanically lower US prices absent something forcing it to.

Also omitted: US prices are high for domestic reasons too — patent thickets and evergreening, PBM spread pricing, and the absence of unified purchasing. Free-riding is one cause among several, presented here as the cause.

Overstated

“Administration and bureaucracy is about 1/3 of total cost” (1:01, 16:05). Definition-dependent and stated at the top of the plausible range. Insurance administration and government administration run roughly 7–8% of national health expenditure in CMS data. Broader definitions that include provider-side billing and compliance reach 15–30%. The claim needs its definition attached or it is not checkable.

“Medical malpractice eats up enormous sums” (1:03). Weak. Mello et al., Health Affairs (2010) put the total cost of the medical liability system — including defensive medicine — at roughly 2.4% of health spending. This is the softest empirical claim in the monologue and the easiest to knock out.

Misleading by omission

The spending-versus-GDP chart is the clearest error

At 16:15–17:05 he shows the health-spending-versus-GDP-per-capita scatter and says the correlation is obvious, then names the outliers below the line — Singapore, Brunei, Saudi Arabia — while omitting that the United States is the largest outlier above it. That is the single most consequential omission in the piece, because the entire “we’re just rich, so we spend a lot” argument depends on the US sitting on the trend line.

Peterson-KFF: the US spent roughly $14,775 per capita in 2024 against a comparable-country average of about $7,860, and 16.7% of GDP in 2023 against a comparable average of 11.0%. KFF states directly that while health spending rises with GDP per capita, the US is an outlier spending more than similarly wealthy countries.

Worse for his argument: Peterson-KFF finds the gap is driven by prices, not volume. The US has roughly half as many in-person doctor consultations per person and shorter hospital stays than peer nations. So the “we’re rich and we buy more care” story is the opposite of what the data shows — we buy less and pay more per unit.

Real numbers, wrong inference

The cancer survival argument defeats itself

At 18:53 he notes that US five-year survival rates are high “despite high screening rates” — treating heavy screening as making the achievement more impressive. It is the confound. Heavy screening mechanically inflates five-year survival through two well-documented biases:

Lead-time bias. Moving the diagnosis date earlier pushes patients across the five-year threshold without delaying a single death.

Overdiagnosis. Screening preferentially detects indolent cancers that would never have progressed. These enter the statistics with effectively indefinite survival and contribute nothing to mortality.

His prostate example (98% US vs ~85% EU) is the textbook case. Modeling studies estimate a mean PSA lead time of roughly 5.4 to 6.9 years, with 23–42% of screen-detected prostate cancers overdiagnosed. The historical parallel is exact: Giuliani’s 2007 campaign ad contrasted 82% US prostate survival against 44% in England — while prostate cancer mortality was about the same in both countries.

The correct metric is age-standardized cancer mortality, not five-year survival. The US does perform respectably on some cancer mortality measures, so the conclusion is not necessarily wrong — but the argument as given cannot establish it, and citing screening intensity as support is backwards.

Wrong

Infant mortality as a measurement artifact (15:03–15:45). Registration practices do differ across countries, so the claim is not baseless. But:

  • The specific UK example is wrong. The UK registers live births regardless of gestational age.
  • Chen, Oster and Williams, “Why Is Infant Mortality Higher in the United States Than in Europe?” (American Economic Journal: Economic Policy, 2016) found reporting differences explain only part of the gap, and that the US disadvantage is concentrated in postneonatal mortality — deaths between one month and one year — which is not a registration artifact at all.
  • The “NBER studies indicate roughly 30% of the mortality gap is data reporting alone” claim is uncited and appears to overstate the paper it is gesturing at. Do not repeat without locating the source.

The demographic-confound argument for life expectancy (11:15–15:00). The strongest-sounding section, and the one that fails hardest.

Removing homicide, overdose, and motor vehicle deaths narrows the US gap. It does not close it. The decisive finding is the 2013 National Research Council / Institute of Medicine report U.S. Health in International Perspective: Shorter Lives, Poorer Health: the US disadvantage persists across essentially all age groups below 75 and holds even among white, insured, college-educated, upper-income Americans with healthy behaviors. If the gap survived every confound he names, the confounds are not the explanation.

Two further problems with the racial-subgroup method:

  • Selection. Asian Americans are a heavily selected immigrant population. Comparing them to Japan does not hold “everything constant except the health system” — it compares a selected migrant cohort to a general population. The same healthy-immigrant effect explains the Hispanic-versus-Mexico comparison he draws, which is a known phenomenon (the “Hispanic paradox”) rather than evidence about system quality.
  • Race as a genetic proxy. “Similar in genetic makeup” is not what racial categories track. Sickle cell trait is ancestry-linked, but ancestry and social race are different variables, and using one as a proxy for the other is exactly the kind of thing he would flag in an opponent.

Needs sourcing before use

  • AI diagnostic study: “90 complex rare disease cases, chatbots doubled the probability of getting it right” (5:29–5:45). Locate the JAMA-family paper.
  • Moderna/Merck mRNA-4157 melanoma results (2:07–2:40) — verify current trial phase and endpoint before citing.
  • The Yale Medicare for All study characterized as claiming 20% savings (30:34). Likely gesturing at Galvani et al., The Lancet (2020), which claimed roughly 13% savings. Find the actual paper before repeating either the claim or the rebuttal.
  • “27 major medical innovations, 20 developed in the US.”

The omission that matters most

The monologue frames the innovation question as private risk capital versus government, with government as the threat. The actual pipeline is public basic science feeding private development. Cleary et al., JAMA Internal Medicine (2018) found NIH funding contributed to published research associated with every one of the 210 new drugs approved between 2010 and 2016.

This does not refute his thesis — the risk-capital argument survives, because translation and trials genuinely are where private capital does the work. But it falsifies the clean public-bad / private-good framing, and it means “cut NIH, protect pharma margins” is not a coherent pro-innovation position.

What to keep

Three things worth carrying forward:

  1. The innovation-financing argument as a real constraint on price-control policy. Any Medicare-for-All costing that assumes lower drug prices with unchanged R&D output owes an account of why. CBO acknowledges this tradeoff; it is not a partisan invention.
  2. Risk-capital depth as an underrated structural explanation for why innovation concentrates in the US.
  3. The diffusion argument — that innovations begin as luxuries and become standard of care — as a genuine response to static equality-of-access framing.

What to discard

  • The life-expectancy confound argument, which the NRC/IOM finding defeats.
  • The infant mortality artifact claim.
  • The spending-tracks-GDP defense, which inverts once the US position on the chart is included.
  • Five-year cancer survival as a system-quality metric.
  • The claim that raising foreign drug prices would lower American ones.

Sources